What kind of people are "engines"? Studies show that they are more likely to be psychopaths, sadists, and narcissists.

Published Date: 17 Feb 2023

Online dating has revolutionized dating by creating more opportunities to meet partners than ever before.

Read Full News

Latest News

Parental Illness Perceptions Drive Poor QoL in Children with Food Allergies

Parental Illness Perceptions Drive Poor QoL in Children with Food Allergies

Exercise May Be as Effective as Therapy for Alleviating Depression Symptoms

Exercise May Be as Effective as Therapy for Alleviating Depression Symptoms

Low-Intensity Ultrasound Brain Stimulation Safely Reduces Depression Symptoms

Low-Intensity Ultrasound Brain Stimulation Safely Reduces Depression Symptoms

Q4 2025 Recap: Psychiatry News and Updates

Q4 2025 Recap: Psychiatry News and Updates

Switching Therapists for Psychotherapy Offers No Advantage in MDD

Switching Therapists for Psychotherapy Offers No Advantage in MDD

Early Week 2 Response Predicts Sustained Benefit with Adjunct Cariprazine in MDD

Early Week 2 Response Predicts Sustained Benefit with Adjunct Cariprazine in MDD

Todays Updates

Rheumatology in 2025: Year in Review Victoria Johnson

The rheumatology year in review highlights FDA approvals and pivotal data readouts.

Nipocalimab Reduces SLE Disease Activity, Meeting JASMINE Study End Point Victoria Johnson

Johnson & Johnson plans to initiate a phase 3 study based off the positive data.

Secondary Analysis Finds Oveporexton Improves Cognitive Function in Adults With Narcolepsy Type 1 Louie Pasculli

Treatment with the orexin-receptor 2 agonist oveporexton was associated with improvements in attention, memory, and executive function in adults with narcolepsy type 1.

Phase 3 Data Readout of EMPEROR Study to Come Earlier, With FDA Submission Expected to Follow Marco Meglio

Those from the clinical community may expect to hear data from the registrational trial assessing zorevunersen in Dravet syndrome by mid-2027.

sBLA Acceptance Positions Efgartigimod as Potential First Therapy for Seronegative Myasthenia Gravis Marco Meglio

The FDA is expected to have a decision on efgartigimod as potentially the first approved therapy for seronegative myasthenia gravis by May 10, 2026.

Additional Phase 2 REVERT IPF Data Shows Greater Fibrosis Reduction With TTI-101

Additional Phase 2 REVERT IPF Data Shows Greater Fibrosis Reduction With TTI-101

Bronchodilator Response Outperforms Genetic Risk in Predicting COPD Progression

Bronchodilator Response Outperforms Genetic Risk in Predicting COPD Progression

Todays Updates

Rheumatology in 2025: Year in Review Victoria Johnson

The rheumatology year in review highlights FDA approvals and pivotal data readouts.

Nipocalimab Reduces SLE Disease Activity, Meeting JASMINE Study End Point Victoria Johnson

Johnson & Johnson plans to initiate a phase 3 study based off the positive data.

Secondary Analysis Finds Oveporexton Improves Cognitive Function in Adults With Narcolepsy Type 1 Louie Pasculli

Treatment with the orexin-receptor 2 agonist oveporexton was associated with improvements in attention, memory, and executive function in adults with narcolepsy type 1.

Phase 3 Data Readout of EMPEROR Study to Come Earlier, With FDA Submission Expected to Follow Marco Meglio

Those from the clinical community may expect to hear data from the registrational trial assessing zorevunersen in Dravet syndrome by mid-2027.

sBLA Acceptance Positions Efgartigimod as Potential First Therapy for Seronegative Myasthenia Gravis Marco Meglio

The FDA is expected to have a decision on efgartigimod as potentially the first approved therapy for seronegative myasthenia gravis by May 10, 2026.

Additional Phase 2 REVERT IPF Data Shows Greater Fibrosis Reduction With TTI-101

Additional Phase 2 REVERT IPF Data Shows Greater Fibrosis Reduction With TTI-101

Bronchodilator Response Outperforms Genetic Risk in Predicting COPD Progression

Bronchodilator Response Outperforms Genetic Risk in Predicting COPD Progression

Latest News

Parental Illness Perceptions Drive Poor QoL in Children with Food Allergies

Exercise May Be as Effective as Therapy for Alleviating Depression Symptoms

Low-Intensity Ultrasound Brain Stimulation Safely Reduces Depression Symptoms

Q4 2025 Recap: Psychiatry News and Updates

Switching Therapists for Psychotherapy Offers No Advantage in MDD

Early Week 2 Response Predicts Sustained Benefit with Adjunct Cariprazine in MDD

News All Time

FDA Releases CRL Detailing Safety Concerns for MDMA-Assisted Therapy in PTSD Chelsie Derman

MDMA’s CRL, now available to the public, cites gaps in safety data, selection bias, and limited durability.

Prenatal Opioid Pain Medications Likely Not Linked to Autism or ADHD Risk Chelsie Derman

A study suggests associations between opioids during pregnancy and neurodevelopmental disorders are mainly due to confounding factors, not causal effects.

Atopic Eczema Linked to Suicidal Ideation in Global Study of 30,000 Adults Chelsie Derman

EADV 2025 findings show patients with atopic eczema face greater risks of depression, anxiety, sleep disorders, and stigmatization.

FDA Initiates Acetaminophen Label Change, Leucovorin Approval for Cerebral Folate Deficiency Abigail Brooks, MA

The Agency initiated an acetaminophen label change to reflect evidence of potential harms in pregnant women and an approval of leucovorin for CFD.

Daily Ammoxetine at 40, 60 mg Outperforms Placebo for MDD in Phase 2 Trial Chelsie Derman

A phase 2 trial demonstrated the effectiveness, safety, and tolerability of ammoxetine (40 and 60 mg) in patients with major depressive disorder.

APhA, Coalition of Autism Scientists Cite Insufficient Data to Support Acetaminophen, Autism Link Abigail Brooks, MA

Both organizations defend the use of Tylenol during pregnancy, citing “rigorous” and “reputable” research suggesting it does not cause autism in children.

5 Psychiatry Headlines You Missed in September 2025 Chelsie Derman

This month in review focuses on innovative therapies in psychiatry, including MM120 for anxiety and ammoxetine for depression, as well as providing safety insights.

Q3 2025 Recap: Psychiatry News and Updates Chelsie Derman

Explore the latest advancements in psychiatry, including FDA updates, emerging therapies, and promising clinical trial results for mental health treatments.

I Tried to End My Life 3 Times: Today, I Help Others Fight for Theirs Diana Guzman, LMHC

Therapist Diana Guzman, LMHC, writes about attempting suicide despite counseling patients battling with suicidal ideation.

FDA Approves Risperidone Extended-Release Injectable for Bipolar I Disorder Chelsie Derman

FDA approves UZEDY, a long-acting risperidone injection, for adults with bipolar I disorder.

Digital Therapeutic Reduces Negative Symptoms of Schizophrenia in Phase 3 Trial Chelsie Derman

A new digital therapeutic, CT-155, shows promise in reducing negative symptoms of schizophrenia.

Soft Drinks Linked to Depression Through Gut Microbiota Alterations Chelsie Derman

New research links soft drink consumption to depression, revealing gut microbiota changes as a potential mediator, particularly in women.

Early Heart Rate Slowing Predicts Magnetic Brain Stimulation Response in MDD Chelsie Derman

Study finds heart rate deceleration within 45 seconds of iTBS may serve as a biomarker for improved depression outcomes, regardless of stimulation site.

Esmethadone Shows Promise as Adjunctive Treatment for Antidepressant Tolerance Chelsie Derman

Post-hoc analysis of a phase 3 trial reveals significant improvements in patients with MDD experiencing tachyphylaxis.

Magnetic Seizure Therapy Rivals ECT, Protects Cognition in Adolescent MDD Chelsie Derman

A study found magnetic seizure therapy matched ECT’s antidepressant efficacy while offering better cognitive preservation and fewer adverse events.

Antidepressants Differ Significantly in Cardiometabolic Side Effects Chelsie Derman

A large analysis reveals clinically relevant differences in weight, blood pressure, and heart rate across 30 antidepressants.

Recommended News For You

New First-Line Option for Advanced ALK-Positive Lung Cancer

How Social Determinants of Health Are Linked to Outcomes in Multiple Myeloma

Eliminating the SRC-3 gene in immune cells causes an efficient, long-lasting anti-cancer response.

PFS in Multiple Myeloma Is Improved by Daratumumab Added to Standard Therapy.

Mouse study finds tirzepatide slowed obesity-associated breast cancer growth

An Intimate Life of Medical Innovation and Charity.

AI catches one-third of interval breast cancers missed at screening

Recommended Articles For You

Unraveling the Mysteries of Hematocrit: How It Impacts Your Health 

The Unseen Threat: Uncovering the Risks of Pancoast Tumor 

Rare Malignant Ovarian Tumors: A Comprehensive Review for Clinicians 

Matrix Metalloproteinases in Stroke: Broad vs. Selective Inhibition Strategies 

Whats more on Hidoc Dr.

Medical Updates
KOL Videos
Surveys
Events

Daily news to keep you up to date

Gain valuable insights with our in-depth KOL Video discussions

Participate and win cash vouchers

Get updates on the latest events happening around the world
Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Review looks at potential treatment targets in the tumor microenvironment.

2.

Studies show that treatment for non-Hodgkin's lymphoma is also focused on the lymphoma.

3.

In a study, immune detection of oral cancers is linked to obesity.

4.

NIH research cuts leave cancer patient facing hard choice

5.

Will a Mindfulness-Based Treatment for Depression Increase Recovery Rates?

1.

A Breakthrough in Multiple Myeloma: Darzalex Delays Disease Progression by 51%

2.

Unraveling the Mysteries of Coagulopathy: A Comprehensive Definition

3.

Uncovering the Role of Pap Smear in Oncology: A New Frontier in Cancer Detection

4.

A Closer Look at White Blood Cells in Urine: Uncovering the Causes and Treatments

5.

CA-125 Test: Why It's Important for Women's Health and Early Detection of Ovarian Cancer

1.

International Lung Cancer Congress®

2.

Genito-Urinary Oncology Summit 2026

3.

Future NRG Oncology Meeting

4.

ISMB 2026 (Intelligent Systems for Molecular Biology)

5.

Annual International Congress on the Future of Breast Cancer East

1.

Pazopanib: A Game-Changer in Managing Advanced Renal Cell Carcinoma - Part III

2.

A Comprehensive Guide to First Line Management of ALK Positive Lung Cancer - Part II

3.

Managing CNS diseases at the point of diagnosis in ALK + NSCLC

4.

Efficient Management of First line ALK-rearranged NSCLC - Part VI

5.

An In-Depth Look At The Signs And Symptoms Of Lymphoma- The Q & A Session

Fastest Growing Medical Platform for Doctors

Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801

Phone :
+1-415-463-3094

Email :
anishagadia@hidoc.co

Quick Links

Drug DatabaseDrug InteractionDiseases Database
KOL VideosKnowledge HubQuizzes
Medical UpdatesEventsAbout Us

© Copyright 2025 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
Home
Profile
Login
bot